These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37035218)

  • 1. Postprandial glucagon-like peptide 1 secretion is associated with urinary albumin excretion in newly diagnosed type 2 diabetes patients.
    Song LL; Wang N; Zhang JP; Yu LP; Chen XP; Zhang B; Yang WY
    World J Diabetes; 2023 Mar; 14(3):279-289. PubMed ID: 37035218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasting and stimulated glucagon-like peptide-1 exhibit a compensatory adaptive response in diabetes and pre-diabetes states: A multi-ethnic comparative study.
    Chong SC; Sukor N; Robert SA; Ng KF; Kamaruddin NA
    Front Endocrinol (Lausanne); 2022; 13():961432. PubMed ID: 36157456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired secretion of glucagon-like peptide 1 during oral glucose tolerance test in patients with newly diagnosed type 2 diabetes mellitus.
    Wang XL; Ye F; Li J; Zhu LY; Feng G; Chang XY; Sun K
    Saudi Med J; 2016 Jan; 37(1):48-54. PubMed ID: 26739974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The changes of gastrointestinal hormones GLP-1, PYY and ghrelin in patients with newly diagnosed type 2 diabetes mellitus].
    Cui T; Ren Y; Ma H; Liu SF; Zhang XX; Yu HL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):774-8. PubMed ID: 24325110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary excretion of glucagon-like peptide 1 (GLP-1) 7-36 amide in human type 2 (non-insulin-dependent) diabetes mellitus.
    Lugari R; Ugolotti D; Dei Cas A; Barilli AL; Iotti M; Marani B; Orlandini A; Gnudi A; Zandomeneghi R
    Horm Metab Res; 2001 Sep; 33(9):568-71. PubMed ID: 11561219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of Plasma Glucagon Levels with Estimated Glomerular Filtration Rate, Albuminuria and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus.
    Huang HX; Shen LL; Huang HY; Zhao LH; Xu F; Zhang DM; Zhang XL; Chen T; Wang XQ; Xie Y; Su JB
    Diabetes Metab J; 2021 Nov; 45(6):868-879. PubMed ID: 33752319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postprandial effects of a whey protein-based multi-ingredient nutritional drink compared with a normal breakfast on glucose, insulin, and active GLP-1 response among type 2 diabetic subjects: a crossover randomised controlled trial.
    Sridonpai P; Prachansuwan A; Praengam K; Tuntipopipat S; Kriengsinyos W
    J Nutr Sci; 2021; 10():e49. PubMed ID: 34290863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes.
    Song L; Kong X; Yang Z; Zhang J; Yang W; Zhang B; Chen X; Wang X
    Diabetes Metab Syndr Obes; 2021; 14():4451-4458. PubMed ID: 34764663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microalbuminuria among Type 1 and Type 2 diabetic patients of African origin in Dar Es Salaam, Tanzania.
    Lutale JJ; Thordarson H; Abbas ZG; Vetvik K
    BMC Nephrol; 2007 Jan; 8():2. PubMed ID: 17224056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.
    Calanna S; Christensen M; Holst JJ; Laferrère B; Gluud LL; Vilsbøll T; Knop FK
    Diabetologia; 2013 May; 56(5):965-72. PubMed ID: 23377698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon.
    Jeppesen PB; Hartmann B; Thulesen J; Hansen BS; Holst JJ; Poulsen SS; Mortensen PB
    Gut; 2000 Sep; 47(3):370-6. PubMed ID: 10940274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans.
    Meier JJ; Ritter PR; Jacob A; Menge BA; Deacon CF; Schmidt WE; Nauck MA; Holst JJ
    J Clin Endocrinol Metab; 2010 Aug; 95(8):4061-5. PubMed ID: 20501678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between metabolic syndrome and meal-induced glucagon like peptide-1 response in type 1 diabetic patients1-1.
    Blaslov K; Bulum T; Zibar K; Duvnjak L
    J Diabetes; 2015 May; 7(3):340-6. PubMed ID: 25042812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent association between the visceral adiposity index and microalbuminuria in patients with newly diagnosed type 2 diabetes.
    Wen J; Yuan H
    Diabetes Metab Res Rev; 2020 Jan; 36(1):e3198. PubMed ID: 31228226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.